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Identity 
Note: There are 2 subtypes of the t(2p;3q); in one type 
the breakpoint on chromosome 2 is assigned to bands 
2p21-23, whereas the breakpoint for the other type of 
breakpoint is localized at 2p15-21. 
Clinics and pathology 
Disease 
Myeloid malignancies: myelodysplastic syndrome 
(MDS) in 1/4 of cases, with various FAB diagnoses 
(refractory anaemia (RA), RA with ringed sideroblasts 
(RARS), RA with excess of blasts (RAEB), RAEB in 
transformation (RAEB-t), and chronic myelomonocytic 
leukemia (CMML)), acute non lymphocytic leukaemia 
(ANLL) in 60% of cases (M2-ANLL in 1/4 of all 
cases), blast crisis of a chronic myelogenous leukaemia 




Partial GTG (Marian Stevens-Kroef, left) and RFA (Anne Hagemeijer, right) banded karyotypes of t(2;3)( p15-23;q26-27) with the distal 
(A) and proximal (B) breakpoint on chromosome 2. 
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Etiology 
1/4 of cases were therapy related leukemias, and 10% 
were BC-CML cases. 
Epidemiology 
At least 50 cases described; sex ratio: 1.33 M/F; 
median age around 50 years, most patients being 
between 30 and 70 year old (range 3-80 years). 
Cytology 
High platelet count, dysmegakaryopoiesis, and 
multilineage dysplasia in 80 to 90% of cases. 
Prognosis 
Median survival 12 months (range 1-53 months), with a 
few patients surviving with bone marrow 
transplantation. 
Cytogenetics 
Note: Heterogeneous breakpoints by cytogenetic and 
FISH analysis; FISH mapping of 2p breakpoints was 
very heterogeneous ranging from p14 or p15 to p23; 
FISH mapping of the 3q breakpoint was within the 
EVI1-MDS region (between RP11-694D5 
(centromeric) and RP11-362K14 (telomeric) in the 
great majority of cases. 
Additional anomalies 
Sole anomaly in 40%, associated with -7 in 30%, with 
del(5q) in 15%, with del(7q) in 10%, with 
t(9;22)(q34;q11) in 10%, and with a complex karyotype 
in 20% of cases. 
Genes involved and Proteins 
Note: Molecular analysis has been performed in only a 
very few cases. In most of these, ectopic expression of 
EVI1 was demonstrated, but rare cases seem not to 
involve this gene. Therefore, characteristics of EVI1 
involvement (high platelet count, multilineage 
dysplasia, monosomy 7, prior history of carcinogen 
exposure and a poor prognosis) may not be present in 
further cases with apparently the same breakpoints. 
The gene(s) involved in chromosome 2 is/are unknown. 
EVI1 
Location: 3q26 
Note: There is a direct correlation between mapping of 
the 3q breakpoint in the above given EVI1-MDS region 
and EVI1 ectopic expression by RT-PCR. Rare case 
with 3q break outside this interval failed to show 
ectopic expression of EVI1. 
DNA / RNA 
EVI1 contains 12 exons. 
Protein 
EVI1 may play an important role in organogenesis, cell 
migration, cell growth, and differentiation. 
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